(Q34516418)

2 August 2017

1 reference

title

Combined androgen blockade: an update. (English)

1 reference

2 August 2017

1

Laurence Klotz

1 reference

2 August 2017

1 May 2006

1 reference

Urologic Clinics of North America

2 August 2017

1 reference

2 August 2017

33

1 reference

2 August 2017

161-6, v-vi

1 reference

2 August 2017

2

1 reference

Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Androgen receptor cross-talk with cell signalling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Transcriptional repression by nuclear hormone receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Analysis of exon 1 mutations in the androgen receptor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Combined androgen blockade in prostate cancer: meta-analyses and associated issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

A re-assessment of the role of combined androgen blockade for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Design and analysis of non-inferiority mortality trials in oncology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.001

10.1016/J.UCL.2005.12.001

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

16631454